ArticleBritish journal of pharmacology2009

Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.

M Hennenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.